Accuracy of MRI for Prediction of Response to Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancer Compared to Other Molecular Types

Abstract

Purpose: The aim of this study was to compare the accuracy of MRI for prediction of response to Neo-adjuvant chemotherapy in Triple negative (TN) breast cancer, with respect to other molecular types. Materials and methods:There were a total of 1610 breast cancers diagnosed between March 2009 and August 2014, out of which 82 patients underwent MRI before and after neo-adjuvant chemotherapy but just before surgery. Triple negative cancers were analysed with respect to others subtypes. Accuracy of MRI for prediction of pathological complete response was compared between different subtypes, by obtaining ROC curves. SPSS (version 21) was used for all data analysis with p value of 0.05 as statistically significant. Results:Out of 82 patients, 29 were Luminal (HR+/HER2 -), 23 were triple negative (HR-, HER2-), 11 HER2 positive (HR-, HER2+) and 19 were of hybrid subtype (HR+/HER2+). Triple negative cancers presented as masses on the pre-chemotherapy MRI scan, were grade 3 on histopathology and show concentric shrinkage following chemotherapy. Triple negative cancers were more likely to have both imaging and pathological complete response following chemotherapy (p=0.055) in contrast to Luminal cancers, which show residual cancer. ROC curves were constructed for prediction of PCR by post chemotherapy MR. For the triple negative sub-group, MR had sensitivity of 0.745 and specificity of 0.700 (p=0.035), with an area under curve (AUC) of 0.745(95% CI 0.526-0.965), which was significantly better compared to other subtypes. Conclusion:Triple negative breast cancers present as masses and show concentric shrinkage following chemotherapy. MRI is most sensitive and specific in predicting response to chemotherapy in the TN group, compared to others subtypes. MRI underestimates residual disease in Luminal cancers.

Evaluation of the Use of Granulocyte Colony-Stimulating Factors (G-CSFs) for Neutropenia Primary Prophylaxis in Solid Tumors at a Tertiary Care Hospital, Retrospective Study

“…Medications such as granulocyte colony-stimulating factors (G-CSFs) are used for primary prophylaxis to reduce the incidence of FN in cancer patients during chemotherapy. G-CSFs increase production and activation of neutrophils and then promote their migration [4,5]. Patients with solid cancers, who do not receive prophylactic G-CSFs, exhibit a higher incidence of FN in comparison to patients who receive G-CSFs as part of the chemotherapy regimen [6][7][8][9].…”